Rochester, NY—Bausch & Lomb has made an equity investment in—and has secured an exclusive option to purchase—AcuFocus Inc., a privately held company in Irvine, CA, that is developing a corneal inlay (ACI 7000) for the treatment of presbyopia....
Bausch + Lomb Corporation, (NYSE/TSX: BLCO) (“Bausch + Lomb” or the “Company”, “we” or “our”), a leading global eye health company dedicated to helping people see better to live better, today announced its first-quarter 2023 financial results.
Bausch+Lomb to introduce Biotrue ONEday for Presbyopia at BCLA in Birmingham.The article previews the Biotrue ONEday, new contact lenses for Presbyopia, to be launched by Bausch & Lomb Inc. in June 2014.EBSCO_AspOptician